ESR1 and breast carcinoma: This double-blind, phase III trial tests whether switching from an aromatase inhibitor to the next-generation oral SERD camizestrant upon detection of an ESR1 mutation in ctDNA can delay clinical progression in HR+/HER2– advanced breast cancer.